46,986 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Acquired by Woodline Partners LP

Woodline Partners LP bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 46,986 shares of the biotechnology company's stock, valued at approximately $5,713,000.

Several other hedge funds have also added to or reduced their stakes in the business. Louisiana State Employees Retirement System boosted its holdings in shares of Sarepta Therapeutics by 0.4% during the 4th quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock worth $3,222,000 after buying an additional 100 shares during the period. EP Wealth Advisors LLC boosted its holdings in shares of Sarepta Therapeutics by 2.2% during the fourth quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock worth $606,000 after acquiring an additional 105 shares during the period. Manchester Capital Management LLC grew its position in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 110 shares during the last quarter. UMB Bank n.a. increased its stake in shares of Sarepta Therapeutics by 36.0% during the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock worth $63,000 after purchasing an additional 138 shares during the period. Finally, CIBC Asset Management Inc lifted its holdings in Sarepta Therapeutics by 5.1% during the 4th quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock worth $347,000 after purchasing an additional 139 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SRPT. Oppenheimer decreased their price objective on Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Guggenheim dropped their price objective on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Scotiabank decreased their target price on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a research report on Thursday, March 20th. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research report on Wednesday, March 19th. Finally, Cantor Fitzgerald cut their price target on Sarepta Therapeutics from $163.00 to $81.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $122.61.

Sarepta Therapeutics Trading Up 1.2%

Shares of Sarepta Therapeutics stock traded up $0.45 on Tuesday, hitting $38.35. The stock had a trading volume of 4,241,932 shares, compared to its average volume of 1,797,194. The stock has a 50 day moving average of $53.76 and a 200 day moving average of $93.63. The firm has a market capitalization of $3.77 billion, a P/E ratio of 30.68 and a beta of 0.85. Sarepta Therapeutics, Inc. has a twelve month low of $34.10 and a twelve month high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). The business had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The company's revenue was up 80.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.73 earnings per share. Sell-side analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Insider Transactions at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now owns 27,812 shares of the company's stock, valued at $2,771,187.68. This represents a 8.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 7.70% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.